Catalyst Crew Technologies Corp., a digital health and artificial intelligence technology company, announced the ongoing development of CardioAI, an artificial intelligence-enabled module designed to support cardiovascular risk assessment and predictive modeling. The platform is intended to assist healthcare providers in analyzing cardiovascular health data and identifying potential clinical risks through AI-driven analytics.
CardioAI's proposed capabilities include heart failure risk modeling, arrhythmia detection algorithms, coronary artery disease risk scoring, and AI-assisted analysis of electrocardiograms and echocardiograms. The platform is being developed to integrate multiple data inputs, including diagnostic imaging, clinical parameters, laboratory results, and patient demographic information, to generate structured outputs intended to support clinical review and care coordination.
The development of CardioAI represents a significant step in addressing cardiovascular disease, which remains one of the leading global health challenges. Dr. Kevin Rodan Levy, Chief Executive Officer of Catalyst Crew Technologies Corp., stated that artificial intelligence can play an important role in supporting earlier detection and more informed clinical decision-making. The platform reflects the company's broader strategy of developing modular, scalable healthcare technologies designed to integrate into real-world healthcare delivery systems.
CardioAI forms part of the company's broader artificial intelligence healthcare platform and is expected to function as a specialized module within Catalyst Crew's digital health ecosystem. Management believes that modular AI systems may support scalable deployment across telehealth services, remote patient monitoring, and technology-enabled healthcare delivery environments. The company intends to integrate CardioAI across its existing and planned healthcare infrastructure initiatives, including its healthcare services coordination platform.
Catalyst Crew Technologies intends to prioritize market development in Latin America, where the company believes artificial intelligence-enabled healthcare technologies may help expand access to cardiovascular screening, support early risk identification, and improve healthcare system efficiency. The region represents a significant opportunity for digital health innovation as healthcare systems increasingly seek scalable solutions to improve diagnostic capabilities and support remote patient care.
As development progresses, CardioAI is being designed to support data-driven insights and clinical decision-support capabilities across multiple points of care. The company intends to continue developing and refining CardioAI and its broader healthcare technology platform while evaluating opportunities for pilot programs, strategic partnerships, and phased market deployment. For more information about the company's initiatives, visit https://catalystcrewai.com or review filings with the U.S. Securities and Exchange Commission at https://www.sec.gov.
